Validation of the GATMO score in predicting non-relapse mortality following hematopoietic cell transplant in multiple myeloma patients
Corresponding Author
Hussein Awada
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Correspondence
Hussein Awada, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Email: [email protected]
Search for more papers by this authorAdel Hajj Ali
Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorMohammad Zeineddine
Department of Internal Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA
Search for more papers by this authorMohammad Rashid
Department of Hematology and Oncology, University of Toledo, Toledo, Ohio, USA
Search for more papers by this authorFaiz Anwer
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorBetty Hamilton
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorCraig Sauter
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorLouis Williams
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorJack Khouri
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorCorresponding Author
Hussein Awada
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Correspondence
Hussein Awada, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Email: [email protected]
Search for more papers by this authorAdel Hajj Ali
Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorMohammad Zeineddine
Department of Internal Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA
Search for more papers by this authorMohammad Rashid
Department of Hematology and Oncology, University of Toledo, Toledo, Ohio, USA
Search for more papers by this authorFaiz Anwer
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorBetty Hamilton
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorCraig Sauter
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorLouis Williams
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorJack Khouri
Multiple Myeloma Program, Blood and Marrow Transplant program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorOpen Research
DATA AVAILABILITY STATEMENT
Data would be made available upon request by the editor.
Supporting Information
| Filename | Description |
|---|---|
| ejh14116-sup-0001-supinfo.docxWord 2007 document , 18.3 KB | Data S1: Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019; 9(4): 44.
- 2Cortez AJ, Dulley FL, Saboya R, et al. Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma. Rev Bras Hematol Hemoter. 2011; 33(1): 10-14.
- 3Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014; 99(3): 408-416.
- 4Li Z, Rubinstein SM, Thota R, et al. Immune-mediated complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016; 22(8): 1368-1375.
- 5Waszczuk-Gajda A, Penack O, Sbianchi G, et al. Complications of autologous stem cell transplantation in multiple myeloma: results from the CALM study. J Clin Med. 2022; 11(12).
- 6Berro M, Chhabra S, Piñana JL, et al. Predicting mortality after autologous transplant: development of a novel risk score. Biol Blood Marrow Transplant. 2020; 26(10): 1828-1832.
- 7Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013; 121(15): 2854-2863.
- 8Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015; 21(8): 1479-1487.
